Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Rare Genetic Disorders of Obesity
NCT03013543Phase 2Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- Mar 2022
- Modality
- Peptides, Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of setmelanotide in obesity (10 cohorts), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment. Started Feb 2017; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03013543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013543.